SYMPHONIX REPORTS FAVORABLE INITIAL PHASE I DATA ON VIBRANT HEARING DEVICE IN IPO PROSPECTUS; $10 MIL. EARMARKED FOR RESEARCH AND FUTURE CLINICAL STUDIES
This article was originally published in The Gray Sheet
Symphonix Devices is hoping that expanded clinical trials of its Vibrant "soundbridge" semi-implantable transducer system will validate the favorable data observed in a Phase I trial. The device is designed to aid patients with moderate to severe hearing impairment. In a preliminary prospectus for a $25 mil. initial public offering, the company estimates about 17 mil. people in the U.S. suffered from this condition in 1994.
You may also be interested in...
Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.
Paracetamol, acetylcysteine and loperamide among list of OTC drugs deemed "essential" by Spain in the fight against coronavirus.
Mylan, in partnership with Indian firm Lupin, will be looking to rival Biogen and Sandoz by introducing an etanercept biosimilar in European markets following a positive opinion by the EMA’s CHMP on Mylan's application.